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Introduction
A recent article from the New England Journal of Medicine
questioned the use of race or ethnicity in assessment algo-
rithms [1]. In the case of osteoporosis, the authors noted that
the US FRAX calculator returns a lower fracture risk for wom-
en who are Black (by a factor of 0.43), Asian (0.50) or
Hispanic (0.53). They conclude that the lower risk for Black,
Asian and minority ethnic (BAME) women may delay inter-
vention with osteoporosis therapy. The NewYork Times goes
further in stating that with FRAX (sic) Black women end up
having a score that makes them less likely to be prescribed
osteoporosis medication than white women who are similar in
all other respects [2].
In the case of osteoporosis and FRAX, the authors do not
appear to have grasped the reality of fracture epidemiology and
risk assessment. In this editorial, we set out the key messages
from the epidemiology of fracture globally, key considerations
in building risk assessment tools, the specific contribution of
race/ethnicity and practical considerations related to any move
to alter race/ethnicity categorisation or remove them entirely.
Heterogeneity of fracture risk
Fracture probability varies markedly in different regions of the
world due to differences in fracture risk and mortality [3, 4]. In
the case of hip fracture, there is a tenfold range in probability
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worldwide which far exceeds the differences in incidence be-
tween sexes within a country (Fig. 1). Ethnicity is not a direct
input variable in the FRAXmodel; these differences therefore
require that FRAX models for a specific country be calibrated
to national fracture and mortality rates. Failure to do so would
result in exceptionally large and avoidable errors in the strat-
ification of risk. Indeed, it would negate the utility of risk
assessment. In addition to 73 country-specific models,
ethnicity-specific models are available in the USA, South
Africa and Singapore. Variations in ethnicity-specific risk of-
ten exceed the differences in risk between sexes. Failure to
calibrate for ethnicity would have adverse consequences
greater than failure to calibrate for sex.
Choosing a risk factor
There are a number of factors to be considered in the selection
of risk factors for case finding. Of particular importance, in the
setting of primary care, is the ease with which they might be
used. For a globally applicable tool, the chosen risk factors
should also be valid in an international setting and their pre-
dictive value stable over time. The use of risk factors for case
finding requires that the risk so identified is responsive to a
therapeutic intervention. It is important to draw the distinction
between reversible risk and reversibility of risk. Age is an
example of an irreversible risk factor, but the risk of fracture
identified by age has reversibility. Thus, pharmacological in-
tervention has an effect on fracture that is independent of age
indicating reversibility of risk [5]. Levels of evidence for the
suitability of risk factors have been developed [6, 7]. The
efficacy of interventions has been tested worldwide in
randomised controlled trials so that ethnicity, race and loca-
tion have a high level of evidence indicating their suitability
for inclusion in risk assessment.
Understanding ethnicity
Vyas et al. [1] contest that, if race does correlate with clinical
outcomes, this does not necessarily justify its inclusion in
diagnostic or predictive tools. Given the complexity of the
determinants of race, it is insufficient to translate a data signal
into a race adjustment without determining what race might
represent in the particular context. Vyas et al. argue that most
race corrections implicitly, if not explicitly, operate on the
assumption that genetic difference tracks reliably with race.
If the empirical differences seen between racial groups were
actually due to genetic differences, then race adjustment might
be justified: different coefficients for different bodies. Whilst
the aspiration that genetics might replace the need for race or
ethnicity is worthy [8], its potential in osteoporosis is presently
limited and restricted to only a single component of fracture
risk (bone mineral density) [9].
The counter argument is that risk factors should be chosen
according to established criteria irrespective of our under-
standing of their basis or their accuracy. A good example is
consumption of alcohol, which is notorious for being inaccu-
rately reported. In general, people who drink alcohol tend to
neglect or underestimate their alcohol consumption [10, 11]. It
matters not whether the return is accurate—only that it pro-
vides a consistent indication of risk, which it does. Thus, we
are more interested in association than causality. The same
goes for race, location and ethnicity.
It is important to recognise that the significance of ethnicity
will vary by location. For example, Black people in the USA
have lower fracture probabilities than Caucasians [12], but the
probability of fracture in USA Black people is much higher
than in African Black people [4] in part due to the higher
fracture rates and lower mortality risks in those from the
USA (Fig. 2). The same holds true for Chinese from Hong
Kong, mainland China and Singapore.
Intervention thresholds
The purpose of FRAX is to characterise fracture risk so that
decisions can be facilitated on the need for treatment and, in
some instances, the type of treatment [6, 13]. This demands
the consideration of intervention thresholds which, in the case
of FRAX, is the 10-year probability of fracture above which
pharmacological intervention should be considered. Several
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Fig. 1 10-year probability of hip fracture in men and women age 65 years
with a prior fragility fracture in countries where a FRAX model is
available. Body mass index set at 25 kg/m2. The diagonal dotted line
denotes the line of equality. Hip fracture probability in women ranged
from 0.5 to more than 5%—a tenfold range. Probabilities in women were
on average 65% higher than in men
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methods have been used to define intervention thresholds [14]
but, in the case of ethnicity-specific models in the USA and
Singapore, use thresholds that apply to all ethnicities [15, 16].
Thus, we challenge the view of Vyas et al. [1] that the incor-
poration of race can exacerbate inequities. Indeed, the con-
verse is true when the gateway to risk assessment is based
on BMD testing rather than fracture probability. If the inter-
vention threshold is set at 20% as in North America [16, 17],
then the equivalent T-score at age 75 years is − 2.8 for
Caucasian women but − 3.8 for Hispanic and Asian women
and − 4.2 for Black women. Thus, the use of FRAX as a
gateway for intervention helps to resolve, rather than exacer-
bate, racial inequalities.
The elephant in the room
A useful measure of health service uptake is the treatment gap
which is defined in its simplest form as the number of people
with a condition or disease who need treatment for it but who
do not get it. The quantification afforded by FRAX has
allowed inequalities in the treatment gap to be identified.
Shortly after the release of FRAX, it was noted that the treat-
ment gap was substantially wider in Black than white patients
at high risk even after adjustment for fracture probability [18,
19]. More recently in the Women’s Health Initiative, those at
high risk and Asian ethnicity had amuch higher likelihood (by
45%) of being on appropriate treatment compared with white
women, whilst in Black/African American, there remained
almost half the likelihood of appropriate medication use
[20]. In addition to racial inequalities, the treatment gap is
higher in men than in women [18, 21, 22]. Paradoxically,
the therapeutic care gap may be particularly wide in the elder-
ly in whom the importance and impact of treatment are high
[23, 24] and particularly in individuals with fracture who re-
side in long-term care [25]. It is perhaps ironic that FRAX has
permitted these inequalities to be recognised.
In the context of osteoporosis, the major issue is disease
discrimination. Many surveys indicate that a small minority of
men and women at high fracture risk actually receive treat-
ment [18, 21, 22, 25, 26]. Fewer than 20% of individuals
receive therapies to reduce the risk of future fracture within
the year following a fracture. Moreover, the treatment gap is
increasing with time [22, 26]. The under-treatment of osteo-
porosis globally has led societies such as the International
Osteoporosis Foundation and the American Society for
Bone and Mineral Research to come together to urgently ad-
dress this global crisis in the management of osteoporosis
[27–29]. This crisis of undertreatment contrasts with the situ-
ation following myocardial infarction, for which condition a
significant care gap has been overcome in the past 15 years:
75% of such individuals now receive beta blockers to help
prevent recurrent myocardial infarction [30].
Studies to date provide little insight into the causes under-
lying the substantial and increasing treatment gap. Factors that
may play a role in the USA include a decline in BMD testing
owing to reimbursement issues and lack of intensive detailing
by pharmaceutical companies. Others point the finger at the
lay press for raising awareness over the last decade of the
potential side effects of the bisphosphonates, such as
osteonecrosis of the jaw, atypical femoral fractures and atrial
fibrillation [26, 28]. Indeed, many doctors, dentists and pa-
tients are now more frightened of the rare but serious side
effects than they are of the disease and the fractures that arise.
Notwithstanding, the lay press is simply the messenger bring-
ing news and opinion from the scientific community, some or
much of which may be ill-judged. The paradox arises in that
we seek to treat individual patients to the highest standards but
Fig. 2 Ethnic-specific 10-year probabilities of a major osteoporotic fracture inmen and women age 65 years with a prior fragility fracture in the USA and
South Africa. Body mass index set at 25 kg/m2
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at the same time disservice and disadvantage the wider osteo-
porosis community [31]. We should not make the same mis-
take with ethnicity and risk assessment
Conclusion
Despite the wide acceptance of the tool, FRAX should not be
considered as a gold standard in patient assessment, but rather
as a reference platform. Thus, the fracture risk estimates de-
rived from FRAX should not be uncritically used in the man-
agement of patients without an appreciation of its limitations
as well as its strengths. In some instances, limitations (e.g. to
experts in bone disease) are perceived as strengths to others
(e.g. primary care physicians) [32, 33]. Notwithstanding, the
calibration of country-specific models and, where appropriate,
ethnicity-specific intranational models, helps direct treatment
to those most at need and avoids unnecessary intervention in
those at low risk, amongst all segments of society. However,
well intentioned, the NEJM article has the potential to domore
harm than good to patients with osteoporosis.
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